Literature DB >> 16154860

The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.

Stefan Knop, Christian Straka, Michael Haen, Renate Schwedes, Holger Hebart, Hermann Einsele.   

Abstract

We performed a dose-escalation study of bendamustine in 31 patients with multiple myeloma that had progressed after high-dose chemotherapy. Bendamustine 100 mg/m2 on days 1 and 2 per cycle was found to be the maximal tolerated dose. The overall response rate was 55% with a median progression-free survival of 26 (0-61) weeks. Toxicity was mild and mainly hematologic.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16154860

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  29 in total

1.  Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Authors:  Suzanne Lentzsch; Amy O'Sullivan; Ryan C Kennedy; Mohammad Abbas; Lijun Dai; Silvana Lalo Pregja; Steve Burt; Michael Boyiadzis; G David Roodman; Markus Y Mapara; Mounzer Agha; John Waas; Yongli Shuai; Daniel Normolle; Jeffrey A Zonder
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

2.  Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Authors:  Heinz Ludwig; Hedwig Kasparu; Clemens Leitgeb; Elisabeth Rauch; Werner Linkesch; Niklas Zojer; Richard Greil; Adelheid Seebacher; Ludek Pour; Adalbert Weißmann; Zdenek Adam
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113

3.  Bendamustine (treanda) for chronic lymphocytic leukemia: a brief overview.

Authors:  Hoyee Leong; Mary Ellen Bonk
Journal:  P T       Date:  2009-02

4.  Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma.

Authors:  K Martin Kortuem; Kaitlyn Zidich; Steven R Schuster; Meaghan L Khan; Victor H Jimenez-Zepeda; Joseph R Mikhael; Rafael Fonseca; A Keith Stewart
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-12-28

5.  The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Authors:  Jacob D Soumerai; Andrew D Zelenetz; Craig H Moskowitz; M Lia Palomba; Paul A Hamlin; Ariela Noy; David J Straus; Alison J Moskowitz; Anas Younes; Matthew J Matasar; Steven M Horwitz; Carol S Portlock; Jason A Konner; Mrinal M Gounder; David M Hyman; Martin H Voss; Matthew G Fury; Devika Gajria; Richard D Carvajal; Alan L Ho; Jan H Beumer; Brian Kiesel; Zhigang Zhang; Alice Chen; Richard F Little; Christine Jarjies; Thu O Dang; Fallon France; Nishant Mishra; John F Gerecitano
Journal:  Clin Cancer Res       Date:  2017-03-17       Impact factor: 12.531

6.  DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.

Authors:  Scott R Goldsmith; Mark A Fiala; Brandon Wang; Mark A Schroeder; Tanya M Wildes; Armin Ghobadi; Keith Stockerl-Goldstein; Ravi Vij
Journal:  Ann Hematol       Date:  2020-03-04       Impact factor: 3.673

Review 7.  Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.

Authors:  Jonathan J Hogan; Brendan M Weiss
Journal:  Clin J Am Soc Nephrol       Date:  2016-07-14       Impact factor: 8.237

Review 8.  Future agents and treatment directions in multiple myeloma.

Authors:  Enrique M Ocio; Constantine S Mitsiades; Robert Z Orlowski; Kenneth C Anderson
Journal:  Expert Rev Hematol       Date:  2013-12-18       Impact factor: 2.929

9.  Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.

Authors:  Wolfram Pönisch; Barbara Moll; Malvina Bourgeois; Marc Andrea; Thomas Schliwa; Simone Heyn; Marion Schmalfeld; Thomas Edelmann; Cornelia Becker; Franz Albert Hoffmann; Andreas Schwarzer; Ute Kreibich; Matthias Egert; Runa Stiegler; Rainer Krahl; Yvonne Remane; Anette Bachmann; Tom Lindner; Lorenz Weidhase; Sirak Petros; Stefan Fricke; Vladan Vucinic; Haifa Al Ali; Dietger Niederwieser
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-18       Impact factor: 4.553

10.  A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.

Authors:  Tomer M Mark; Whitney Reid; Ruben Niesvizky; Usama Gergis; Roger Pearse; Sebastian Mayer; June Greenberg; Morton Coleman; Koen Van Besien; Tsiporah Shore
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-20       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.